Focusing on the overexpression of MDM4 in MCPyV-positive MCC cell lines, Park et al. used Lenalidomide, which is a selective MDM4 inhibitor, which when used alone exhibited only a modest increase in p53 levels in MCC cell lines. The gene discussed is MDM4; the disease is Merkel cell skin cancer.